Crimson Publishers Publish With Us Reprints e-Books Video articles


Open Access Biostatistics & Bioinformatics

Formulation & Evaluation of Sustained Release Matrix Tablet of Repaglinide

Submission: December 12, 2017; Published: February 23, 2018

DOI: 10.31031/OABB.2018.01.000509

ISSN: 2578-0247
Volume1 Issue2


The aim of present is to develop & evaluate Sustained release matrix tablet of Repaglinide. Repaglinide is an effective antihyperglycemic. But owing to its shorter half life it needs frequent administration. In present study, an attempt has been made to develop Sustained release matrix tablet of Repaglinide thereby reducing its frequency of administration & other dose related side effects. Various grades of HPMC (K4M, 100M & 15M) were used as hydrophilic matrix polymer. Croscarmellose was used as swelling agent. Total 9 formulations were prepared in trial batches. The formulation was evaluated for various pre compression & post compression parameters. All the formulations showed compliance with the pharmacopoeial standards. On the basis of evaluated parameters formulation F9 was considered to be the best one. Formulation F9 containing polymer HPMC showed 99.15% invitro drug release profile. The release data for formulation F9 was fitted to various mathematical models like zero order, first order, Krosmeyer Peppas & Higuchi model. It was observed that drug follows zero order & Higuchi model.

Keywords: Repaglinide; Sustained Release Matrix; HPMC (K4M, K100M, K15M); Croscarmellose; Wet Granulation

Get access to the full text of this article

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137